Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0025 in advanced or metastatic squamous NSCLC
NCT07360132Phase 3Not yet recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Jan 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sotiburafusp alfa in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. Primary endpoint: Progression-Free Survival at 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sotiburafusp alfa
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT07360132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07360132.